Literature DB >> 15930282

Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility.

Eric C Seales1, Gustavo A Jurado, Brian A Brunson, John K Wakefield, Andra R Frost, Susan L Bellis.   

Abstract

Colon adenocarcinomas are known to express elevated levels of alpha2-6 sialylation and increased activity of ST6Gal-I, the Golgi glycosyltransferase that creates alpha2-6 linkages. Elevated ST6Gal-I positively correlates with metastasis and poor survival, and therefore ST6Gal-I-mediated hypersialylation likely plays a role in colorectal tumor invasion. Previously we found that oncogenic ras (present in roughly 50% of colon adenocarcinomas) up-regulates ST6Gal-I and, in turn, increases sialylation of beta1 integrin adhesion receptors in colon epithelial cells. However, we wanted to know if this pattern held true in vivo and, if so, how beta1 hypersialylation might contribute to colon tumor progression. In the present study, we find that beta1 integrins from colon adenocarcinomas consistently carry higher levels of alpha2-6 sialic acid. To explore the effects of increased alpha2-6 sialylation on beta1-integrin function, we stably expressed ST6Gal-I in a colon epithelial cell line lacking endogenous ST6Gal-I. ST6Gal-I expressors (with alpha2-6 sialylated beta1 integrins) exhibited up-regulated attachment to collagen I and laminin and increased haptotactic migration toward collagen I, relative to parental cells (with completely unsialylated beta1 integrins). Blockade of ST6Gal-I expression with short interfering RNA reversed collagen binding back to the level of ST6Gal-I nonexpressors, confirming that alpha2-6 sialylation regulates beta1 integrin function. Finally, we show that beta1 integrins from ST6Gal-I expressors have increased association with talin, a marker for integrin activation. Collectively, these findings suggest that beta1 hypersialylation may augment colon tumor progression by altering cell preference for certain extracellular matrix milieus, as well as by stimulating cell migration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15930282     DOI: 10.1158/0008-5472.CAN-04-3117

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  134 in total

1.  NEU1 and NEU3 sialidase activity expressed in human lung microvascular endothelia: NEU1 restrains endothelial cell migration, whereas NEU3 does not.

Authors:  Alan S Cross; Sang Won Hyun; Alba Miranda-Ribera; Chiguang Feng; Anguo Liu; Chinh Nguyen; Lei Zhang; Irina G Luzina; Sergei P Atamas; William S Twaddell; Wei Guang; Erik P Lillehoj; Adam C Puché; Wei Huang; Lai-Xi Wang; Antonino Passaniti; Simeon E Goldblum
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

2.  Metabolic flux increases glycoprotein sialylation: implications for cell adhesion and cancer metastasis.

Authors:  Ruben T Almaraz; Yuan Tian; Rahul Bhattarcharya; Elaine Tan; Shih-Hsun Chen; Matthew R Dallas; Li Chen; Zhen Zhang; Hui Zhang; Konstantinos Konstantopoulos; Kevin J Yarema
Journal:  Mol Cell Proteomics       Date:  2012-03-28       Impact factor: 5.911

3.  alpha2,6-hyposialylation of c-Met abolishes cell motility of ST6Gal-I-knockdown HCT116 cells.

Authors:  Jin Qian; Cai-Hua Zhu; Shuai Tang; Ai-Jun Shen; Jing Ai; Jing Li; Mei-Yu Geng; Jian Ding
Journal:  Acta Pharmacol Sin       Date:  2009-06-01       Impact factor: 6.150

4.  Proteolytic shedding of ST6Gal-I by BACE1 regulates the glycosylation and function of alpha4beta1 integrins.

Authors:  Alencia V Woodard-Grice; Alexis C McBrayer; John K Wakefield; Ya Zhuo; Susan L Bellis
Journal:  J Biol Chem       Date:  2008-07-23       Impact factor: 5.157

5.  N-glycosylation of the I-like domain of beta1 integrin is essential for beta1 integrin expression and biological function: identification of the minimal N-glycosylation requirement for alpha5beta1.

Authors:  Tomoya Isaji; Yuya Sato; Tomohiko Fukuda; Jianguo Gu
Journal:  J Biol Chem       Date:  2009-03-04       Impact factor: 5.157

6.  The Glycosyltransferase ST6Gal-I Protects Tumor Cells against Serum Growth Factor Withdrawal by Enhancing Survival Signaling and Proliferative Potential.

Authors:  Colleen M Britain; Kaitlyn A Dorsett; Susan L Bellis
Journal:  J Biol Chem       Date:  2017-01-30       Impact factor: 5.157

7.  Enhancing RPE Cell-Based Therapy Outcomes for AMD: The Role of Bruch's Membrane.

Authors:  Janosch P Heller; Keith R Martin
Journal:  Transl Vis Sci Technol       Date:  2014-07-03       Impact factor: 3.283

8.  Altered eosinophil profile in mice with ST6Gal-1 deficiency: an additional role for ST6Gal-1 generated by the P1 promoter in regulating allergic inflammation.

Authors:  Mehrab Nasirikenari; E V Chandrasekaran; Khushi L Matta; Brahm H Segal; Paul N Bogner; Amit A Lugade; Yasmin Thanavala; James J Lee; Joseph T Y Lau
Journal:  J Leukoc Biol       Date:  2009-12-09       Impact factor: 4.962

Review 9.  Sweetening the pot: adding glycosylation to the biomarker discovery equation.

Authors:  Penelope M Drake; Wonryeon Cho; Bensheng Li; Akraporn Prakobphol; Eric Johansen; N Leigh Anderson; Fred E Regnier; Bradford W Gibson; Susan J Fisher
Journal:  Clin Chem       Date:  2009-12-03       Impact factor: 8.327

Review 10.  Glycosylation in cancer: mechanisms and clinical implications.

Authors:  Salomé S Pinho; Celso A Reis
Journal:  Nat Rev Cancer       Date:  2015-08-20       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.